Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Metagenomi, Inc. Common Stock (MGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: MGX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.8
1 Year Target Price $12.8
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.62% | Avg. Invested days 6 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 78.50M USD | Price to earnings Ratio - | 1Y Target Price 12.8 |
Price to earnings Ratio - | 1Y Target Price 12.8 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 1.23 - 5.10 | Updated Date 07/17/2025 |
52 Weeks Range 1.23 - 5.10 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -172.21% | Operating Margin (TTM) -674.1% |
Management Effectiveness
Return on Assets (TTM) -15.37% | Return on Equity (TTM) -31.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -103779491 | Price to Sales(TTM) 1.73 |
Enterprise Value -103779491 | Price to Sales(TTM) 1.73 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 37381500 | Shares Floating 23232225 |
Shares Outstanding 37381500 | Shares Floating 23232225 | ||
Percent Insiders 28.2 | Percent Institutions 26.49 |
Upturn AI SWOT
Metagenomi, Inc. Common Stock
Company Overview
History and Background
Metagenomi, Inc. is a gene editing company founded in 2018, pioneering a data-driven approach to discover and develop novel gene editing tools derived from uncultivated microbes. Their focus is on advancing the field of gene therapy through innovative enzymes.
Core Business Areas
- Gene Editing Technology: Discovery and development of novel gene editing tools, including CRISPR systems, using metagenomics and computational biology.
- Therapeutic Development: Applying gene editing technologies to develop therapeutic candidates for various diseases, including genetic disorders.
- Partnerships and Licensing: Establishing collaborations with pharmaceutical and biotechnology companies for the development and commercialization of gene editing therapies.
Leadership and Structure
Brian C. Roberts is the CEO. The organizational structure includes research & development, therapeutic development, and business development teams.
Top Products and Market Share
Key Offerings
- Novel Gene Editing Enzymes: Metagenomi's primary offering is its library of novel gene editing enzymes discovered through metagenomics. Market share is still nascent as they are in the development and pre-clinical stages. Competitors include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA).
- Therapeutic Programs: Metagenomi is developing therapeutic programs targeting various genetic diseases. These programs are currently in pre-clinical or early clinical stages, so market share data is not yet available. Competitors include companies developing gene therapies for similar indications.
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, driven by advances in CRISPR technology and the potential to cure genetic diseases. The market is competitive, with numerous companies developing and commercializing gene editing tools and therapies.
Positioning
Metagenomi is positioned as a leader in the discovery and development of novel gene editing enzymes through its unique metagenomics approach. Their competitive advantage lies in the potential for improved efficacy and safety compared to existing gene editing technologies.
Total Addressable Market (TAM)
The total addressable market for gene editing is estimated to reach tens of billions of dollars in the coming years. Metagenomi is positioned to capture a significant share of this market through its innovative technology and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Novel gene editing technology
- Unique metagenomics approach
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Early-stage development
- Limited clinical data
- High R&D costs
- Dependence on partnerships
Opportunities
- Expanding therapeutic pipeline
- Strategic partnerships and licensing agreements
- Advancements in gene editing technology
- Growing market demand for gene therapies
Threats
- Competition from established gene editing companies
- Regulatory hurdles
- Clinical trial failures
- Ethical concerns related to gene editing
Competitors and Market Share
Key Competitors
- CRISPR Therapeutics (CRSP)
- Editas Medicine (EDIT)
- Intellia Therapeutics (NTLA)
Competitive Landscape
Metagenomi is well-positioned with novel technology, but faces competition from more established players in the gene editing space with more advanced clinical programs.
Major Acquisitions
Inscripta, Inc (Strategic Collaboration Not an Acquisition)
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: Multi-target discovery collaboration to identify novel CRISPR systems. No acquisition price since its a collaboration.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by research and development progress, patent filings, and partnership announcements.
Future Projections: Future growth is expected to be driven by the advancement of therapeutic programs into clinical trials and the signing of strategic partnerships.
Recent Initiatives: Recent initiatives include expansion of the gene editing enzyme library and advancement of lead therapeutic programs.
Summary
Metagenomi is a promising early-stage gene editing company with a unique metagenomics approach. Its strengths lie in its novel technology and strong IP portfolio, but it faces challenges related to early-stage development and competition from larger players. Successful development of its therapeutic programs and strategic partnerships are crucial for future growth. The company has a high potential, but also significant risks associated with biotechnology development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Please consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Metagenomi, Inc. Common Stock
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2024-02-09 | Co-Founder, CEO & Chairman of the Board Dr. Brian Charles Thomas Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 176 | Website https://metagenomi.co |
Full time employees 176 | Website https://metagenomi.co | ||
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.